PDF(1385 KB)
PDF(1385 KB)
PDF(1385 KB)
鼠IL-10基因腺病毒载体的构建及在骨髓间充质干细胞中的表达
Construction of rat interleukin-10 adenoviral vector and its expression in bone marrow mesenchymal stem cells
目的 构建携带鼠IL-10（rIL-10）基因重组腺病毒载体，并探讨其能否在鼠骨髓间充质干细胞（MSCs）中稳定表达。方法 rIL-10引物经PCR扩增rIL-10 cDNA序列，将回收到的656 bp rIL-10 DNA片段克隆入pcDNA3.1载体中，构建pcDNA3.1-IL-10，将其与腺病毒载体共转染HEK293细胞，进行细胞内同源重组，经测序及聚合酶链反应（PCR）鉴定重组是否成功；反复冻融裂解HEK293细胞，将获得的含rIL-10基因的病毒液感染MSCs，Western blot法检测rIL-10在MSCs中的表达。结果 经测序及PCR验证，rIL-10基因腺病毒载体构建成功，病毒滴度达4×109 PFU/mL。含rIL-10基因的病毒液体外感染MSCs后，可检测到IL-10的表达。结论 构建重组腺病毒能够介导rIL-10基因在MSCs中的稳定表达，为下一步基因移植治疗炎症性肠病提供基础。
Objective To construct the recombinant adenoviral vector carrying the rat interleukin-10 (rIL-10) gene, and to investigate whether it is stably expressed in bone marrow mesenchymal stem cells. Methods The rIL-10 gene was amplified by PCR from template rIL-10 cDNA, and the recovered 656 bp rIL-10 DNA fragment was cloned into pcDNA3.1 to construct pcDNA3.1-IL-10. Then HEK293 cells were transfected with pcDNA3.1-IL-10 and adenoviral vector for homologous recombination, and sequencing and PCR were used to evaluate whether recombination was successful. HEK293 cells were lysed by repeated freeze-thaw cycles, and bone marrow mesenchymal stem cells were infected with the virus solution containing the rIL-10 gene. Western blot was used to measure the expression of rIL-10 in bone marrow mesenchymal stem cells. Results Sequencing and PCR verified that the rIL-10 adenoviral vector was successfully constructed, with a virus titer of 4×109 PFU/mL. The expression of IL-10 was detected after bone marrow mesenchymal stem cells were infected by the virus solution containing the rIL-10 gene. Conclusions The constructed rIL-10 recombinant adenovirus can mediate the stable expression of rIL-10 gene in bone marrow mesenchymal stem cells, which provides a basis for gene transplantation therapy of inflammatory bowel disease.
炎症性肠病 / IL-10基因 / 腺病毒载体 / 骨髓间充质干细胞 / 大鼠
Inflammatory bowel disease / Interleukin-10 gene / Adenoviral vector / Bone marrow mesenchymal stem cell / Rats
[1] Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study[J]. BMC Gastroenterol, 2009, 9:66.
[2] Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function[J]. Immunity, 2014, 40(5):706-719.
[3] Christodoulou K, Wiskin AE, Gibson J, et al. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes[J]. Gut, 2013, 62(7):977-984.
[4] Shim JO, Seo JK. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations[J]. J Hum Genet, 2014, 59(6):337-341.
[5] Lin Z, Wang Z, Hegarty JP, et al. Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease[J]. World J Gastroenterol, 2017, 23(27):4897-4909.
[6] Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis[J]. Cell, 1993, 75(2):263-274.
[7] Shim JO, Hwang S, Yang HR, et al. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis[J]. Eur J Gastroenterol Hepatol, 2013, 25(10):1235-1240.
[8] Doecke JD, Simms LA, Zhao ZZ, et al. Genetic susceptibility in IBD:overlap between ulcerative colitis and Crohn's disease[J]. Inflamm Bowel Dis, 2013, 19(2):240-245.
[9] Arthur A, Zannettino A, Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair[J]. J Cell Physiol, 2009, 218(2):237-245.
[10] Sémont A, Mouiseddine M, François A, et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis[J]. Cell Death Differ, 2010, 17(6):952-961.
[11] Chen QQ, Yan L, Wang CZ, et al. Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses[J]. World J Gastroenterol, 2013, 19(29):4702-4717.
[12] He XW, He XS, Lian L, et al. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice[J]. Dig Dis Sci, 2012, 57(12):3136-3144.
[13] Qi Y, Jiang D, Sindrilaru A, et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds[J]. J Invest Dermatol, 2014, 134(2):526-537.
[14] Yang J, Liu XX, Fan H, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis[J]. PLoS One, 2015, 10(10):e0140551.
[15] Anderson P, Souza-Moreira L, Morell M, et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis[J]. Gut, 2013, 62(8):1131-1141.
[16] Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD[J]. Am J Gastroenterol, 2011, 106(4):685-698.
[17] Schreiber S, Heinig T, Thiele HG, et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease[J]. Gastroenterology, 1995, 108(5):1434-1444.
[18] Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor[J]. Annu Rev Immunol, 2001, 19:683-765.
[19] Tilg H, van Montfrans C, van den Ende A, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma[J]. Gut, 2002, 50(2):191-195.
[20] Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10[J]. Science, 2000, 289(5483):1352-1355.
[21] Dave M, Mehta K, Luther J, et al. Mesenchymal stem cell therapy for inflammatory bowel disease:a systematic review and meta-analysis[J]. Inflamm Bowel Dis, 2015, 21(11):2696-2707.
[22] Niu GC, Liu L, Zheng L, et al. Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice[J]. BMC Gastroenterol, 2018, 18(1):127.
湖南省卫生厅（B2012-102）。
